- within Food, Drugs, Healthcare and Life Sciences topic(s)
- in United States
- with readers working within the Business & Consumer Services and Securities & Investment industries
Agricultural biotechnology is advancing quickly – but the regulatory path to market can be anything but straightforward. In this episode, hosts Lauren Petrin and Dr. Alex Stanton explain how the Coordinated Framework splits oversight across USDA, FDA, and EPA, and why gene editing raises new questions that legacy rules weren’t designed to answer. They also examine how the heightened focus on agriculture as a matter of national security is shaping calls for risk-based regulatory modernization – and how policy and litigation setbacks, including the invalidation of USDA’s Secure Rule, can slow that progress.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]
